Proceedings · Session S-480 · filed November 19, 2026

Lab Technology & MethodsSession paper

Sydney team reports seven-week human liver perfusion record

A Sydney team says automated perfusion kept one donated human liver alive for seven weeks at 37 °C, but formal results are pending and transplant utility is unresolved.

By Tom Whitfield5 min read969 words

Summary

  • Seven weeks: A Sydney team reports keeping a donated human liver alive at about 37 °C.
  • 55 livers: Automated perfusion produced an average survival time of about four weeks, triple the manual group’s result.
  • Two weeks: The previous Swiss liver record lasted roughly two weeks.
  • 2022: A Swiss team transplanted a damaged liver after three days of perfusion, then the internal-organ record.
  • Four days: Aeternum Life Technologies will support a planned Sydney trial using low-quality perfused livers.
A human liver has been kept alive outside the body for a record seven weeks
FigureA human liver has been kept alive outside the body for a record seven weeks — AI-generated

By Tom Whitfield

A Sydney research team reports keeping a donated human liver alive for seven weeks at normothermic body temperature, about 37 °C, more than three times the roughly two-week Swiss record set in Switzerland several years ago. The result remains unpublished, so the measurement protocol and the liver’s condition at the end cannot yet be assessed.

The work took place in Sydney under Carlo Pulitano, a transplant surgeon at Royal Prince Alfred Hospital and professor at the University of Sydney. His Extended Organ Perfusion System connected automated pumps and sensors to the liver, delivering nutrients and blood while removing waste. Pulitano likens the setup to “an artificial body.”

Pulitano attributes the record to automating systems that previously needed manual adjustment. At a 2026 meeting in Switzerland, the team described perfusing 55 human livers one after another. Livers on the automated system averaged about four weeks, triple the survival time of the manual group; one reached seven weeks.

The account gives no automated-subgroup size, donor mix or assay endpoints, limiting comparison with manual perfusion. Until those data appear in a paper, the duration remains a preliminary result rather than a validated benchmark.

“Our group is the only one in the world to have maintained a human liver under fully normothermic, physiological conditions for seven weeks,” Pulitano said.

What does seven-week survival mean for transplantation?

Most donor organs survive only a few hours in ice buckets during a race to the transplant center. Over the past decade, surgeons have increasingly used perfusion systems that pump warm or cold fluid through an organ, which can double holding time. Perfusion has also restarted hearts after death and kept them beating outside the body.

At the University of Oklahoma, transplant surgeon Paulo Martins says about half the kidneys he transplants now receive perfusion. That choice can add $100,000 to a transplant’s cost. The seven-week result therefore changes a logistics problem before it changes a clinical protocol: teams still need evidence that long-held organs function after implantation.

Longer support could create repair time as well as transport time. Scientists report that perfused organs can begin repairing themselves and become stronger after a day or so. In 2022, a Swiss team transplanted a damaged liver after three days of perfusion, then the longest an internal organ had remained outside a body before successful transplantation.

Waldemar Hoffmann, CEO and cofounder of Apersys, a startup formed to commercialize the technology, supplied that history. He and Pulitano agree on the larger goal, which the Sydney team calls “time-unlimited liver preservation.” Aeternum Life Technologies, Pulitano’s startup, will support a planned Sydney trial transplanting low-quality livers held on perfusion for four days.

“The key question is what the purpose for a seven-week perfusion would be,” Hoffmann said. Specialists believe Pulitano’s record is real, but they do not know the liver’s health after seven weeks, whether a surgeon would want or need it, or what the extra time would enable. The pending paper leaves clinical endpoints unstated.

What research could longer organ life support enable?

Martins sees uses beyond transplantation: artificial wombs, new forms of organ manufacturing and direct experiments on human organs outside the body for extended periods. These remain proposals, not demonstrated applications. Pulitano has already divided a liver and attached the sections to the machine. “If that works,” he said, the approach could multiply one donor liver into several full-size organs.

Pulitano says long-term machine perfusion could help new organs grow. Surgeons remove half of a donor’s liver during living donation, and both halves regrow to nearly full volume in about two months. The proposed use remains conditional because successful growth in the machine has not been reported.

“It’s important to have people thinking outside the box and pushing the limits and creating possibilities for things that, right now, sometimes we don’t even have a need for but are going to be needed in the future,” Martins said. “That’s how science moves.”

US company Bexorg already uses perfusion pumps to reanimate human brains for studies of experimental drugs. The company perfuses brains for about one day and aims to extend that to two weeks. Pulitano says livers could provide a comparable model; he has already added gene therapies to perfused livers.

“It gives us a living human organ model for translational research that no animal system can match, because the biology, the immunology, and the drug responses are human from the outset,” Pulitano said.

Altos Labs, a billionaire-backed longevity startup, has filed patent WO2024155957A1 describing attempts to introduce reprogramming genes into animal livers maintained outside the body. Its scientists have speculated about temporarily disconnecting a failing organ while it remains in a patient, then treating it with powerful gene-based therapies on a perfusion machine without risking the rest of the body.

Who is organizing the field around machine perfusion?

Doctors studying organ life support have formed two societies. One, founded by Martins, is the International Society for Organ Preservation and Perfusion Therapy; its inaugural meeting is scheduled for this year in Italy. The other, based in China, launched in August to advance “organ medicine.”

Researchers at the First Affiliated Hospital of Sun Yat-Sen University describe “organ medicine” as work on whole organs kept alive through “bionic maintenance.” The new institutional interest extends preservation beyond clinical logistics, but it also raises the need for common measures of organ function, recovery and transplant benefit.

“What is exploding is the idea of this technology that clearly goes beyond simply organ preservation,” Pulitano said. “Basically, that’s a concept that’s entirely new.”

For the field, the next decisive tests are publication of the seven-week case and a protocol for the planned four-day Sydney transplant trial.

via easl.eu (Original)

Filed under

  • machine-perfusion
  • liver-preservation
  • organ-transplantation
  • normothermic-perfusion
  • translational-research
Share this article:

More from Tom Whitfield

Tom Whitfield

Show full bio

Senior reporter covering technology and product news in research and development at Hypothesis Wire.

280 articles

References

  1. Liver kept alive 7 weeks ex-body as Sila lands $1B battery deal
  2. Pig Kidneys Revived After a Year at -150 °C in Cryopreservation First
  3. DARPA Bets $73 Million on Shelf-Stable Blood for 2029 Deployment
  4. Harvard-Led HuBMAP Atlas Is AI-Ready, but 501 Donors Fall Short
  5. Stable Pools Move Biologics Off the Clone-First Path

« Previous articleNext article »